A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. 1990

G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
Department of Psychiatry, University of Würzburg, FRG.

A double-blind multicentre study comparing the efficacy and safety of remoxipride in relation to haloperidol was conducted in 160 inpatients with schizophrenic illness diagnosed according to DSM-III. The study period was 4 weeks. The mean daily dose of remoxipride (whether given twice or three times daily) during the last week of treatment was 395 mg; the corresponding dose of haloperidol was 17 mg per day. No significant difference in therapeutic efficacy was found; Brief Psychiatric Rating Scale (BPRS) median total scores dropped from 41 to 20 (remoxipride twice daily, n = 51), 43 to 20 (remoxipride three times daily, n = 44) 40 to 19 (haloperidol three times daily, n = 48) at last valid rating. According to Clinical Global Impression (CGI) 68% in the remoxipride twice daily, 58% in the three times daily and 60% in the haloperidol group were very much or much improved. Treatment-emergent extrapyramidal checklist symptoms (hypokinesia, rigidity and tremor) were statistically significantly more frequent and more severe during haloperidol than during remoxipride treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients. Also, haloperidol treated patients had a significantly higher frequency of extrapyramidal symptoms on 8 out of 10 items of the Simpson and Angus scale.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females

Related Publications

G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
September 1991, Pharmacopsychiatry,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Psychopharmacology bulletin,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
November 1994, Acta psychiatrica Scandinavica,
G Laux, and E Klieser, and H G Schröder, and V Dittmann, and B Unterweger, and H Schubert, and P König, and H W Schöny, and J Bunse, and H Beckmann
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Copied contents to your clipboard!